Loading...
OTCM
NMTRQ
Market cap0kUSD
Mar 12, Last price  
0.00USD
1D
0.00%
1Q
0.00%
Jan 2017
-100.00%
IPO
-100.00%
Name

9 Meters Biopharma Inc

Chart & Performance

D1W1MN
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
85.21%
Rev. gr., 5y
-38.97%
Revenues
0k
3,444,00011,343,0008,266,0004,065,0001,883,00000000
Net income
-46m
L+23.59%
-3,435,000-11,057,000-8,741,000-6,213,000-7,925,000-24,162,279-28,873,956-65,542,712-36,826,588-45,515,779
CFO
-37m
L+26.34%
-3,872,000-7,452,000-1,730,000-8,427,000-4,002,000-15,169,330-17,967,992-19,409,786-29,478,275-37,243,217

Profile

9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as well as in Phase IIa clinical trial for treatment of multi-system inflammatory syndrome; and Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 2 clinical trial to treat short bowel syndrome. It also develops NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease; NM-136, a humanized monoclonal antibody for targeted obesity disorders; and NM-004, a double-cleaved mesalamine with an immunomodulator for rare and/or orphan indications. The company is based in Raleigh, North Carolina.
IPO date
Jul 08, 2016
Employees
10
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
42,017
Unusual Expense (Income)
NOPBT
(42,017)
NOPBT Margin
Operating Taxes
1,749
Tax Rate
NOPAT
(43,766)
Net income
(45,516)
23.59%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
19,678
Long-term debt
165
Deferred revenue
Other long-term liabilities
Net debt
7,196
Cash flow
Cash from operating activities
(37,243)
CAPEX
(3)
Cash from investing activities
(3)
Cash from financing activities
19,912
FCF
(43,706)
Balance
Cash
12,646
Long term investments
Excess cash
12,646
Stockholders' equity
(212,606)
Invested Capital
234,736
ROIC
ROCE
EV
Common stock shares outstanding
12,956
Price
1.26
28.74%
Market cap
16,324
37.22%
EV
23,520
EBITDA
(42,009)
EV/EBITDA
Interest
2,667
Interest/NOPBT